Teva Reports 33% Growth Across Three Innovative Brands
Tel Aviv, Israel, November 3, 2026 Teva Pharmaceutical Industries Ltd. has reported strong growth across its three key innovative...
neuroscience
Advertisement
Teva Acquires BioXcel Assets to Expand Neuroscience Pipeline
Tel Aviv, Israel, October 27, 2026 Teva Pharmaceuticals has completed the acquisition of neuroscience assets from BioXcel Therapeutics, including...
Newron Expands ENIGMA-TRS 2 Enrollment Outside U.S.
MILAN, Italy and MORRISTOWN, N.J. September 25, 2026 — Newron Pharmaceuticals announced that the U.S. clinical hold on enrollment...
Filana Gains FDA Lift of Simufilam Clinical Hold
AUSTIN, Texas — September 22, 2026 Filana Therapeutics announced that the U.S. Food and Drug Administration has lifted the...
Otsuka Reports Phase 3b SIMTRIYO Data in ADHD and Anxiety
PRINCETON, N.J. and TOKYO, Japan — September 18, 2026 Otsuka Pharmaceutical presented new Phase 3b results for SIMTRIYO® (centanafadine)...
Advertisements
Alkermes Reports Positive Phase 1b ADHD Data for ALKS 7290
DUBLIN — September 21, 2026 Alkermes announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290,...
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Mania Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
AbbVie Reports New Real-World VRAYLAR Data in Depression
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
ReEmerge Raises $37M to Advance Brain Injury Technology
Boston, Massachusetts, U.S., September 15, 2026 ReEmerge, Inc. has emerged from stealth with an oversubscribed $37 million Series A...
QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
Advertisement
